Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641962 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04641962 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 34 participants.
The verdict
NCT04641962, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the dose response of Bocidelpar on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.
Interventions
- DRUG Placebo
- DRUG Bocidelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2024-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04641962
The ClinicalTrials.gov registry entry for NCT04641962 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04641962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04641962 about?
NCT04641962 is a clinical study titled "A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy". The purpose of this study was to evaluate the dose response of Bocidelpar on functional improvement relative to placebo, safety, and tolerability in participants with Primary Mitochondrial Myopathy.
What is the current status of trial NCT04641962?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2021-05-24. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT04641962?
The interventions under investigation include: Placebo (DRUG), Bocidelpar (DRUG).
Who is sponsoring clinical trial NCT04641962?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.